The application of AI in telehealth to allow doctors to make real-time, data-driven rich choices is a key component in generating a better patient experience and improved health outcomes.
The mHealth industry is rapidly disrupting traditional healthcare delivery by leveraging the power of mobile communication technologies and wearable devices.
Growing pressure on the manufacturing industry from rising prices, new regulations and supply chain uncertainty have accelerated medtech’s digital transformation. COVID-19, in particular, has encouraged medical manufacturers to adopt more resilient and agile working practices. New technology can enable process changes and business strategies that help medical manufacturers become more flexible and responsive to changing…
If teams across regulatory, quality and safety functions—as well as further across the life sciences enterprise—are to be able to think and operate in more agile and dynamic ways to achieve what is necessary, then the way that they generate, manage and store documents and data needs to change fundamentally. Regulatory changes (e.g., towards data-driven submissions activity, more dynamic item/label tracking, etc.) are prompting some of this change, but cannot be relied upon exclusively to drive the process improvements now needed.
As the country emerges from the COVID-19 pandemic, it’s time to evaluate and assess lessons learned and find any possible silver linings derived from the crisis. This includes telehealth and the use of remote technology.
EMA’s IDMP is not the pinnacle of data-based product/regulatory information management. It is simply the first in what will be a long line of digital requirements to emerge globally, across all facets of life sciences. This article reviews best practices for companies looking to maximize the ROI of their data-driven process transformation initiatives by making them more broadly fit for the future.
As the focal point of care moves away from the facility and into the home, care providers and health systems will lean more heavily on connected health devices in advancing and expanding the future of healthcare.
MedTech Intelligence recently sat down with Peter O‘Blenis, CEO of Evidence Partners to discuss challenges reviewers face throughout their literature review process in the context of regulatory compliance, and to talk about the upcoming virtual event, Evidence Matters 2021.
To achieve success, a medical device startup must build a sophisticated data architecture specifically designed to deliver maximum value for its customers’ use cases. However, it’s extremely difficult to build such an architecture—especially given early-stage budget constraints. That’s why startups must wisely synch their data architecture spending with their funding rounds.
As more medtech companies take advantage of the game-changing technology to innovate and advance products, they must anticipate the need to obtain trustworthy, evidence-based comprehensive data—and be prepared to do their own due diligence to verify the chain of evidence and meet increasingly stringent regulatory requirements.
